Journal
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 27, Issue 5, Pages 235-237Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2006.03.010
Keywords
-
Categories
Funding
- Intramural NIH HHS Funding Source: Medline
Ask authors/readers for more resources
Angiotensin II (Ang 11) has been implicated in the development of cardiovascular disorders and chronic kidney disease (CKD). Ang 11 causes renal lesions through the activation of tumor necrosis factor (TNF)-alpha-converting enzyme (TACE, also called a disintegrin and a metalloproteinase domain 17) and the release of transforming growth factor (TGF)-alpha, which binds to and activates the epidermal growth factor receptor. Renal lesions such as glomerulosclerosis, tubular atrophy, fibrosis, mononuclear cell infiltration and proteinuria following chronic Ang 11 infusion are substantially reduced in mice lacking TGF-alpha and those given a specific TACE inhibitor. These findings indicate that the selective inhibition of renal TACE could have therapeutic potential in the treatment of CKD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available